Need help finding what you are looking for?
Contact Us
PUBLISHER: BCC Research | PRODUCT CODE: 1889185
PUBLISHER: BCC Research | PRODUCT CODE: 1889185
Global GLP-1 Analogues Market
PUBLISHED:
PAGES: 85 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
This report presents detailed information on glucagon-like peptide-1 (GLP-1) analogues. It examines market trends for GLP-1 analogues using data from 2024, estimates for 2025, and projected compound annual growth rates (CAGRs) through 2030 (the forecast period of 2025-2030). The report also covers regional markets for GLP-1 analogues. The GLP-1 analogue market is segmented by route of administration into oral and injection. By region, the market is divided into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America.
Report Scope
This report provides detailed information on glucagon-like peptide-1 (GLP-1) analogues. It analyzes market trends for GLP-1 analogues, with data from 2024, estimates from 2025, projections of compound annual growth rates (CAGRs) through 2030 (the forecast period 2025-2030) and regional markets for GLP-1 analogues. This report highlights the current and future market potential of GLP-1 analogues and provides a detailed analysis of the competitive environment. It covers regulatory scenarios, drivers, restraints and opportunities, along with the market projections for 2030 and market share for key companies.
The GLP-1 analogue market is segmented by route of administration into oral and injection. By region, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The regional segment covers a detailed analysis of major countries such as the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China and India. For market estimates, 2024 is used as the base year, with forecasts for 2025 and a projected value for 2030.
The report aims to:
- Analyze the market for GLP-1 analogues.
- Analyze the global market size and market segments.
- Understand market constraints and drivers.
- Provide detailed market forecasts for 2030.
- Assess market share, competitiveness and industry structure.
- Identify potential long-term impacts on the GLP-1 analogue market.
Report Includes
- An overview of the current and future global markets for GLP-1 analogues
- In-depth analysis of global market trends, featuring historical revenue data for 2022-2024, estimated figures for 2025, as well as forecasts for 2030. This analysis includes projections of compound annual growth rates (CAGRs) through 2030
- Estimates of the size and revenue prospects of the global market, along with a market share analysis by route of administration, indication and region
- Facts and figures pertaining to the market dynamics, technical advances, regulations and the impact of macroeconomic factors
- An analysis of patents, emerging trends and developments in the industry
- Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
- Profiles of the leading companies
Product Code: PHM289A
Table of Contents
Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
- Market Dynamics and Growth Factors
- Emerging Technologies
- Segmental Analysis
- Regional Analysis
- Conclusion
Chapter 2 Market Overview
- Overview
- Analysis of Macroeconomic Factors
- Impact of U.S. Tariffs on the Pharmaceutical Industry
- Healthcare Expenditure
- Market Demand and Demographics
- Porter's Five Forces Analysis
- Bargaining Power of Buyers (High)
- Bargaining Power of Suppliers (Moderate to High)
- Potential for New Entrants (Low)
- Threat of Substitutes (Moderate)
- Competitiveness in the Industry (High)
Chapter 3 Market Dynamics
- Market Dynamics
- Market Drivers
- Increasing Cases of Diabetes and Obesity
- Increasing Awareness of Diagnosis and Treatment Options for Diabetes
- Strong R&D Pipeline
- Market Restraints
- Product Failure
- High Barriers for New Entrants
- Market Opportunities
- Extended Therapeutic Uses
- Integration in Telehealth and Weight Management Program
Chapter 4 Regulatory Landscape
- Regulatory Dynamics
- U.S.
- Europe
- Japan
- China
Chapter 5 Emerging Technologies and Pipeline Analysis
- Emerging Trends/Technologies
- Next-Generation Multi-Receptor Agonists
- Innovative Drug Delivery Methods
- Expanded Therapeutic Indications
- Pipeline Analysis
- Key Takeaways
- Patent Analysis
- Key Takeaways
Chapter 6 Market Segment Analysis
- Segmentation Breakdown
- Global GLP-1 Analogues Market by Route of Administration
- Key Takeaways
- Injectable
- Oral
- Geographic Breakdown
- Global GLP-1 Analogue Market by Region
- Key Takeaways
- North America
- Europe
- Asia-Pacific
- South America
- Middle East and Africa
Chapter 7 Competitive Intelligence
- Key Takeaways
- Competitive Landscape
- Company Share Analysis
Chapter 8 Sustainability in GLP-1 Analogues: ESG Perspective
- Introduction to ESG
- Sustainability in the GLP-1 Analogue Market
- ESG Perspective
- Environmental Impact
- Social Impact
- Governance Impact
- Conclusion
Chapter 9 Appendix
- Methodology
- Sources
- Abbreviations
- Company Profiles
- HANSOH PHARMACEUTICAL GROUP CO. LTD.
- LILLY USA LLC.
- NOVO NORDISK A/S
- SANOFI
- SHANGHAI BENEMAE PHARMACEUTICAL CORP.
- TEVA PHARMACEUTICAL INDUSTRIES LTD.
- Emerging Players
Product Code: PHM289A
List of Tables
- Summary Table : Global Market for GLP-1 Analogues, by Region, Through 2030
- Table 1 : Global Health Expenditure, by Selected Country, 2021-2023
- Table 2 : Worldwide Diabetic Adult Population , by Region, 2000-2050(Thousands)
- Table 3 : FDA-Approved GLP-1 Receptor Agonists
- Table 4 : Selected Clinical Trials for GLP-1 Receptor Agonists in Phases 3 and 4
- Table 5 : Selected Granted Patents Related to GLP-1 Analogues, 2022-2024
- Table 6 : Global Market for GLP-1 Analogues, by Route of Administration, Through 2030
- Table 7 : Global Market for Injectable GLP-1 Analogues, by Region, Through 2030
- Table 8 : Global Market for Oral GLP-1 Analogues, by Region, Through 2030
- Table 9 : Global Market for GLP-1 Analogues, by Region, Through 2030
- Table 10 : North American Diabetes Statistics and Prevalence, 2011-2050
- Table 11 : North American Market for GLP-1 Analogues, by Route of Administration, Through 2030
- Table 12 : North American Market for GLP-1 Analogues, by Country, Through 2030
- Table 13 : European Diabetes Statistics and Prevalence, 2011-2050
- Table 14 : European Market for GLP-1 Analogues, by Route of Administration, Through 2030
- Table 15 : European Market for GLP-1 Analogues, by Country, Through 2030
- Table 16 : South East Asian Diabetes Statistics and Prevalence, 2011-2050
- Table 17 : Asia-Pacific Market for GLP-1 Analogues, by Route of Administration, Through 2030
- Table 18 : Asia-Pacific Market for GLP-1 Analogues, by Country, Through 2030
- Table 19 : South and Central American Diabetes Statistics and Prevalence, 2011-2050
- Table 20 : South American Market for GLP-1 Analogues, by Route of Administration, Through 2030
- Table 21 : South American Market for GLP-1 Analogues, by Country, Through 2030
- Table 22 : Middle East and North Africa Diabetes Statistics and Prevalence, 2011-2050
- Table 23 : MEA Market for GLP-1 Analogues, by Route of Administration, Through 2030
- Table 24 : MEA Market for GLP-1 Analogues, by Sub-Region, Through 2030
- Table 25 : Product Revenue, by Company, 2023 and 2024
- Table 26 : Information Sources for this Report
- Table 27 : Abbreviations Used in this Report
- Table 28 : Hansoh Pharmaceutical Group Co. Ltd.: Company Snapshot
- Table 29 : Hansoh Pharmaceutical Group Co. Ltd.: Financial Performance, FY 2023 and 2024
- Table 30 : Hansoh Pharmaceutical Group Co. Ltd.: Product Portfolio
- Table 31 : Hansoh Pharmaceutical Group Co. Ltd.: News/Key Developments, 2025
- Table 32 : Lilly USA LLC.: Company Snapshot
- Table 33 : Lilly USA LLC.: Financial Performance, FY 2023 and 2024
- Table 34 : Lilly USA LLC.: Product Portfolio
- Table 35 : Lilly USA LLC.: News/Key Developments, 2025
- Table 36 : Novo Nordisk A/S: Company Snapshot
- Table 37 : Novo Nordisk A/S: Financial Performance, FY 2023 and 2024
- Table 38 : Novo Nordisk A/S: Product Portfolio
- Table 39 : Novo Nordisk A/S: News/Key Developments, 2023-2025
- Table 40 : Sanofi: Company Snapshot
- Table 41 : Sanofi: Financial Performance, FY 2023 and 2024
- Table 42 : Sanofi: Product Portfolio
- Table 43 : Sanofi: News/Key Developments, 2024
- Table 44 : Shanghai Benemae Pharmaceutical Corp.: Company Snapshot
- Table 45 : Shanghai Benemae Pharmaceutical Corp.: Product Portfolio
- Table 46 : Shanghai Benemae Pharmaceutical Corp.: News/Key Developments, 2023
- Table 47 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
- Table 48 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2023 and 2024
- Table 49 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
- Table 50 : Teva Pharmaceutical Industries Ltd.: News/Key Developments, 2024 and 2025
- Table 51 : Few Emerging Players in the GLP1 Analogue Market
List of Figures
- Summary Figure : Global Market Shares of GLP-1 Analogues, by Region, 2024
- Figure 1 : Porter's Five Forces Analysis of the GLP-1 Analogue Market
- Figure 2 : Market Dynamics of GLP-1 Analogues
- Figure 3 : Clinical Trial Studies of GLP-1 Drugs, by Trial Phase, 2022-2025*
- Figure 4 : Global Market Shares of GLP-1 Analogues, by Route of Administration, 2024
- Figure 5 : Global Market Shares of Injectable GLP-1 Analogues, by Region, 2024
- Figure 6 : Global Market Shares of Oral GLP-1 Analogues, by Region, 2024
- Figure 7 : Global Market Shares of GLP-1 Analogues, by Region, 2024
- Figure 8 : North American Market Shares of GLP-1 Analogues, by Route of Administration, 2024
- Figure 9 : North American Market Shares of GLP-1 Analogues, by Country, 2024
- Figure 10 : European Market Shares of GLP-1 Analogues, by Route of Administration, 2024
- Figure 11 : European Market Shares of GLP-1 Analogues, by Country, 2024
- Figure 12 : Asia-Pacific Market Shares of GLP-1 Analogues, by Route of Administration, 2024
- Figure 13 : Asia-Pacific Market Shares of GLP-1 Analogues, by Country, 2024
- Figure 14 : South American Market Shares of GLP-1 Analogues, by Route of Administration, 2024
- Figure 15 : South American Market Shares of GLP-1 Analogues, by Country, 2024
- Figure 16 : MEA Market Shares of GLP-1 Analogues, by Route of Administration, 2024
- Figure 17 : MEA Market Shares of GLP-1 Analogues, by Sub-Region, 2024
- Figure 18 : Global Market Shares of GLP-1 Analogues, by Company, 2024
- Figure 19 : Pillars of ESG
- Figure 20 : Advantages of ESG for Companies
- Figure 21 : Lilly USA LLC.: Revenue Share, by Country/Region, FY 2024
- Figure 22 : Novo Nordisk A/S: Revenue Share, by Business Unit, FY 2024
- Figure 23 : Novo Nordisk A/S: Revenue Share, by Country/Region, FY 2024
- Figure 24 : SANOFI: Revenue Share, by Country/Region, FY 2024
- Figure 25 : Teva Pharmaceutical Industries Ltd.: Revenue Share, by Business Unit, 2024
- Figure 26 : Teva Pharmaceutical Industries Ltd.: Revenue Share, by Country/Region, 2024
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.